

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM338168

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	Security Agreement		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Cipher Pharmaceuticals Inc.		04/13/2015	CORPORATION: CANADA
RECEIVING PARTY DATA			
Name:	Athyrium Opprtunities II Acquisition LP		
Street Address:	530 Fifth Avenue, Floor 25		
City:	New York		
State/Country:	NEW YORK		
Postal Code:	10036		
Entity Type:	LIMITED PARTNERSHIP: DELAWARE		
PROPERTY NUMBERS Total: 3			
Property Type	Number	Word Mark	
Registration Number:	4700183	MELANOVUS ONCOLOGY	
Registration Number:	4103049	CONZIP	
Registration Number:	3403114	LIPOFEN	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Email:	marina.kelly@thomsonreuters.com		
Correspondent Name:	Brian Wagner		
Address Line 1:	4400 Easton Commons Way Suite 125		
Address Line 2:	CT Lien Solutions		
Address Line 4:	Columbus, OHIO 43219		
NAME OF SUBMITTER:	Brian Wagner		
SIGNATURE:	/Marina Kelly, Thomson Reuters/		
DATE SIGNED:	04/14/2015		
Total Attachments: 5			
source=39 - Notice of Security in Trademarks (USPTO) - Cipher (2)#page1.tif			
source=39 - Notice of Security in Trademarks (USPTO) - Cipher (2)#page2.tif			
source=39 - Notice of Security in Trademarks (USPTO) - Cipher (2)#page3.tif			
source=39 - Notice of Security in Trademarks (USPTO) - Cipher (2)#page4.tif			

OP \$90.00 4700183

NOTICE
OF
GRANT OF SECURITY INTEREST
IN
TRADEMARKS

United States Patent and Trademark Office


Ladies and Gentlemen:

Please be advised that pursuant to the Security Agreement dated as of April 13, 2015 (as the same may be amended, modified, restated or supplemented from time to time, the "Security Agreement") by and among the Grantors from time to time party thereto (each a "Grantor" and collectively, the "Grantors") and Athyrium Opportunities II Acquisition LP, as Collateral Agent (the "Collateral Agent") for the Secured Parties referenced therein, the undersigned Grantor has granted a continuing security interest in and continuing lien upon, the trademarks, trademark licenses and trademark applications set forth on Schedule 1 attached hereto to the Collateral Agent for the ratable benefit of the Secured Parties.

The undersigned Grantor and the Collateral Agent, on behalf of the Secured Parties, hereby acknowledge and agree that the security interest in the trademarks, trademark licenses and trademark applications set forth on Schedule 1 attached hereto (i) may only be terminated in accordance with the terms of the Security Agreement and (ii) is not to be construed as an assignment of any trademark, trademark license or trademark application.

Very truly yours,

CIPHER PHARMACEUTICALS INC.


By: 
Name: NORMAN EVANS
Title: CEO

Acknowledged and Accepted:

ATHYRIUM OPPORTUNITIES II ACQUISITION LP,
as Collateral Agent

By: Athyrium Opportunities Associates II LP, Its General Partner

By: Athyrium Opportunities Associates II GP LLC, Its General Partner

By: 

Name: Andrew Hyman

Title: Authorized Signatory

SCHEDULE 1

Mark	Serial No. Filing Date	Reg. No. Reg. Date	Status
MELANOVUS ONCOLOGY	85673693 July 11, 2012	4700183 March 10, 2015	Registered
CONZIP	85175001 November 11, 2010	4103049 February 21, 2012	Registered
LIPOFEN	78688955 August 9, 2005	3403114 March 25, 2008	Registered

6441714